G. Russ

Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection.

The haemagglutinin (HA) of influenza A virus consists of two glycopolypeptides designated HA1 and HA2. Antibodies recognizing HA1 inhibit virus haemagglutination, neutralize virus infectivity and provide good protection against infection, but do not cross-react with the HA of other subtypes. Little is known regarding the biological activities of antibodies against HA2. To study the role of antibodies directed against HA2 during influenza virus infection, two vaccinia virus recombinants (rVVs) were used expressing chimeric molecules of HA, in which HA1 and HA2 were derived from different HA subtypes. The KG-11 recombinant expressed HA1 from A/PR/8/34 (H1N1) virus and HA2 from A/NT/60 (H3N2) virus, whilst KG-12 recombinant expressed HA1 from A/NT/60 virus and HA2 from A/PR/8/34 virus. Immunization of BALB/c mice with rVV expressing HA2 of the HA subtype homologous to the challenge virus [A/PR/8/34 (H1N1) or A/Mississippi/1/85 (H3N2)] did not prevent virus infection, but nevertheless resulted in an increase in mice survival and faster elimination of virus from the lungs. Passive immunization with antibodies purified from mice immunized with rVVs confirmed that antibodies against HA2 were responsible for the described effect on virus infection. Based on the facts that HA2 is a rather conserved part of the HA and that antibodies against HA2, as shown here, may moderate virus infection, future vaccine design should deal with the problem of how to increase the HA2 antibody response.

Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients.

It has been suggested that HLA-G antigens may provide tumor cells with an effective immune escape mechanism. So far mostly solid tumors have been analyzed; HLA-G antigen was only exceptionally detected. To further examine HLA-G expression, patients were chosen with different forms of leukemia: AML (25), CML (4), ALL (9), CLL (8), HCL (2) and NHL (3). Using flow cytometry with three HLA-G specific mAbs (87G, 01G and MEM-G/9), western blotting with two specific mAbs (4H84 and MEM-G/1) and RT-PCR, neither HLA-G antigen nor mRNA for any HLA-G isoform was detected. These results strongly suggest that HLA-G antigen is not expressed in freshly isolated human leukemia cells and therefore is not involved in their escape from immune attack.

Dissociation of β2-microglobulin is responsible for selective reduction of HLA class I antigenicity following acid treatment of cells

Beta 2-Microglobulin (beta 2 m) dissociated from surface HLA class I complex following exposure of cells to low pH and was detected in supernatant by radioimmunoprecipitation with specific monoclonal antibodies (mAbs). As the concn of beta 2m in supernatant increased, the binding of mAbs, specific for HLA class I heavy chains associated with beta 2m, to the cell surface declined. Binding of mAb specific for free HLA class I heavy chain to the cell surface increased after acid treatment. Reassociation with exogenous beta 2m confirmed increase in the number of free HLA class I heavy chains on surface of the cells after their exposure to low pH and also at least partially restored the reactivity with mAbs specific to HLA class I heavy chains associated with beta 2m. Dissociation of beta 2m from CD1 complex following acid treatment was also accompanied with the changes in antigenicity of cell surface CD1 molecules.

The molecular weight determination of proteins and glycoproteins of RNA enveloped viruses by polyacrylamide gel electrophoresis in SDS

Abstract The apparent molecular weights for glycoproteins of four RNA enveloped viruses — influenza virus, NDV, VSV and AMV, calculated relative to protein standards depend upon the percent of acrylamide used. Such anomaly is not observed for other proteins of these viruses. The irregular behaviour of glycoproteins resulted from their lesser capacity to bind SDS.

The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody IIB4, which recognizes antigenic site B on influenza A virus haemagglutinin.

Monoclonal antibody (MAb) IIB4 displays a rare combination of virus neutralization (VN) activity and broad cross-reactivity with influenza A virus strains of the H3 subtype isolated in a period from 1973 to 1988. The epitope of this antibody has been identified as around HA1 residues 198, 199 and 201. Here we report that residues 155, 159, 188, 189 and 193 also influence the binding of this antibody. We have used this antibody to study the relationship between antibody affinity and VN activity. Using one MAb and a single epitope on the haemagglutinin (HA) of different influenza viruses we found a strong positive correlation between effective affinity and VN activity of MAb IIB4. A 10-fold increase in effective affinity corresponded to the 2000-fold increase in VN titre. It follows from the law of mass action that for an effective affinity K=9x10(8) l/mol, 50% VN was achieved at approx. 10% occupation of HA spikes with antibody. In contrast, for an effective affinity K=6x10(7) l/mol, to achieve 50% VN, occupation of up to 98% of HA spikes was required. An effective affinity about K=6x10(7) l/mol thus represents the limiting value for VN because a further decrease in the affinity cannot be compensated by a higher concentration of antibody.

Antibodies to PB1-F2 protein are induced in response to influenza A virus infection.

PB1-F2 is a small influenza A virus (IAV) protein encoded by an alternative (+1) reading frame of the PB1 gene. While dispensable for IAV replication in cultured cells, PB1-F2 has been implicated in IAV pathogenicity. To better understand PB1-F2 expression in vivo and its immunogenicity, we analyzed anti-PB1-F2 antibodies (Abs) in sera of mice infected intranasally (i.n.) with A/PR/8/34 (H1N1) virus and human acute and convalescent sera collected from the influenza H3N2 winter 2003–2004 epidemic. We explored a number of methods for detecting anti-PB1-F2 Abs, finding that PB1-F2-specific Abs could clearly be detected via immunoprecipitation or immunofluorescence assays using both immune mouse and human convalescent sera. Importantly, paired human sera exhibited similar increases in HI titers and PB1-F2-specific Abs. This study indicates that PB1-F2 is expressed in sufficient quantities in mice and humans infected with IAV to elicit an Ab response, supporting the biological relevance of this intriguing accessory protein.

Monoclonal antibodies demonstrate accessible HA2 epitopes in minor subpopulation of native influenza virus haemagglutinin molecules

SummaryHaemagglutinin (HA) was detected on the surface of influenza virus infected cell with monoclonal antibodies (MAbs) against both HA glycopolypeptides, HA1 and HA2, however, the reactivity of HA2-specific MAbs was remarkably lower as compared with HA1-specific MAbs. Quantitative analysis with two MAbs, IB8 (anti-HA1) and IIF4 (anti-HA2) respectively, revealed that HA2 epitope was reachable for antibody only in minor subpopulation of the HA representing approximately 7% of all molecules (spikes). The basis of the HA heterogeneity is discussed.

Human cell surface proteins selectively assembled into vesicular stomatitis virus virions

Vesicular stomatitis virus (VSV) selectively assembled proteins from human cells into progeny virions. These proteins can be surface labeled before infection with 125I, and when purified virus was examined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, only two or three bands of proteins (Mr around 100K) were seen. Antisera to these proteins were produced, using as immunizing antigen VSV tsO45 mutant, defective in assembly of G protein, which had been made at the nonpermissive temperature in the three human tumor cell lines, HeLa (cervical carcinoma), T47D (breast carcinoma), and HMB2 (melanoma). After absorption with wild-type VSV, each of the antisera displayed a different pattern of reactivity; at least three antigenic specificities were detected. Two of them, corresponding to antigens selected by VSV from HeLa and T47D, were to some extent related and they showed an association mainly with epithelial cell-derived gynecological tumors, but they were absent in carcinomas of lung or of digestive tract. These (or related) antigens were expressed in a lower level in some normal tissues, mainly in ovaries. Antigen(s) assembled by VSV from the melanoma cell line was entirely different and appeared to be associated with cell growth. The grounds for selective assembly of these specific proteins by VSV are not clear; they either share with viral surface glycoproteins some physical or structural properties, which are critical for incorporation into the viral envelope, or conceivably they even may represent uncleaved precursor proteins coded by env genes of incomplete genomes of endogenous human retroviruses.

Changes in the influenza virus haemagglutinin at acid pH detected by monoclonal antibodies to glycopolypeptides HA1 and HA2

SummaryMonoclonal antibodies (Mabs) specific to the HA 1 and HA 2 subunits of the influenza virus haemagglutinin (HA) were used to show that changes in the antigenicity of the HA molecule at acid pH involve both HA subunits. In solid phase RIA (intact virus adsorbed) the acid-induced change was detected in the form of greatly increased binding of anti-HA 1 Mabs (IVA 1 and IVG 6) and anti-HA 2 Mab (IIF 4). This increased binding could be most probably explained by alterations in accessibility of epitopes to the corresponding Mabs. Other Mabs examined (including 7 anti-HA 2 Mabs specific to 3 independent antigenic sites) had either similar reactivities with both untreated and pH 5-treated virus or slightly but significantly increased binding to pH 5-treated virus. No effect of pH 5 treatment on antibody binding was observed with purified BHA in solid phase RIA. Nevertheless a similar pH 5-induced conformational change in the isolated BHA (like in intact viral HA in solid phase RIA) was detected in competitive binding assay carried out in liquid phase.

A DNA vaccine expressing PB1 protein of influenza A virus protects mice against virus infection

Although influenza DNA vaccine research has focused mainly on viral hemagglutinin and has led to promising results, other virion proteins have also shown some protective potential. In this work, we explored the potential of a DNA vaccine based on the PB1 protein to protect BALB/c mice against lethal influenza A virus infection. The DNA vaccine consisted of pTriEx4 plasmid expressing PB1. As a positive control, a pTriEx4 plasmid expressing influenza A virus HA was used. Two weeks after three subcutaneous doses of DNA vaccine, the mice were challenged intranasally with 1 LD50 of A/Puerto Rico/8/34 (H1N1) virus, and PB1- and HA-specific antibodies, survival rate, body weight change, viral mRNA load, infectious virus titer in the lungs, cytokines IL-2, IL-4 and IL-10, and granzyme-B were measured. The results showed that (i) the PB1-expressing DNA vaccine provided a fair protective immunity in the mouse model and (ii) viral structural proteins such as PB1 represent promising antigens for DNA vaccination against influenza A.